ALNY240621C145000
- 18.44
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
Selling US$7.7m Of Alnylam Pharmaceuticals Stock Rewarded Insiders
Alnylam Pharmaceuticals Is Maintained at Buy by UBS
Alnylam Pharmaceuticals Is Maintained at Buy by UBS
Express News | Alnylam Pharmaceuticals Inc : UBS Raises Target Price to $288 From $253
One graphic to understand | the June bull and bear stocklist of U.S. stocks is released! Optional consumer and technology sectors are performing strongly, Arm rose more than 38%, and Adobe rose nearly 23%.
The three major US stock indexes rose collectively this month, putting a perfect end to the first half of the year. Large-cap tech stocks continued their rally, driving the Nasdaq up by 6.71% this month, the best performer. The S&P 500 rose 3.89% this month and the Dow Jones rose 1.23%.
UBS Initiates Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Announces Target Price $288
UBS analyst Eliana Merle initiates coverage on $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and sets the target price at $288.According to TipRanks data, the analyst has a success rate of 40.
Alnylam Pharmaceuticals(ALNY.US) Director Sells US$2.04 Million in Common Stock
$Alnylam Pharmaceuticals(ALNY.US)$ Director SCHULMAN AMY W sold 8,500 shares of common stock on Jun 25, 2024 at an average price of $240 for a total value of $2.04 million.Source: Announcement What is
Peering Into Alnylam Pharmaceuticals's Recent Short Interest
Alnylam Pharmaceuticals's (NYSE:ALNY) short percent of float has fallen 14.16% since its last report. The company recently reported that it has 2.13 million shares sold short, which is 1.94% of all re
Alnylam Pharmaceuticals Is Maintained at Outperform by RBC Capital
Alnylam Pharmaceuticals Is Maintained at Outperform by RBC Capital
Alnylam Pharmaceuticals Price Target Raised to $265.00/Share From $250.00 by RBC Capital
Alnylam Pharmaceuticals Price Target Raised to $265.00/Share From $250.00 by RBC Capital
Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $295
Stifel analyst Paul Matteis maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and adjusts the target price from $247 to $295.According to TipRanks data, the analyst has a success rate of
Stifel Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $295
Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $215 to $295.
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $265
RBC Capital analyst Luca Issi maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and adjusts the target price from $250 to $265.According to TipRanks data, the analyst has a success rate
US Stock | Amazon joins the "Trillion-Dollar Market Cap Club"; Rivian soars more than 23% overnight.
Microsoft hit a new all-time high overnight, with a cumulative increase of over 20% since the beginning of the year; Fedex rose more than 15% overnight, exceeding expectations for the 2025 fiscal year guidance and receiving a bullish rating from Goldman Sachs.
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $250
Morgan Stanley analyst Michael Ulz maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a hold rating, and maintains the target price at $250.According to TipRanks data, the analyst has a success rate of
Express News | Alnylam Pharmaceuticals Inc : RBC Raises Target Price to $265 From $250
Alnylam Pharmaceuticals(ALNY.US) Director Sells US$7.16 Million in Common Stock
$Alnylam Pharmaceuticals(ALNY.US)$ Director PYOTT DAVID E I sold 32,450 shares of common stock on Jun 24, 2024 at an average price of $221 for a total value of $7.16 million.Source: Announcement What
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing
David E I Pyott, Director, on June 24, 2024, sold 32,450 shares in Alnylam Pharmaceuticals (ALNY) for $7,161,360. Following the Form 4 filing with the SEC, Pyott has control over a total of 28,036 sha
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.
Alnylam Pharmaceuticals on Track for Record High Close -- Data Talk
Alnylam Pharmaceuticals, Inc (ALNY) is currently at $245.68, up $5.53 or 2.3% --Would be new all-time high (Based on available data back to May 28, 2004) --Would be the first record close since Dec.
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $234 to $291
On Jun 26, major Wall Street analysts update their ratings for $Alnylam Pharmaceuticals(ALNY.US)$, with price targets ranging from $234 to $291.Morgan Stanley analyst Michael Ulz maintains with a hold